Table II.
Baseline participant characteristics for the 3-month cohort (n = 524).
| 40.13 (SD = 8.6)
|
||
|---|---|---|
| Mean age, years | % | (N) |
| Gender | ||
| Male | 65 | (335) |
| Female | 34 | (179) |
| Transgender | 1 | (1) |
| Race/Ethnicity | ||
| African American | 66 | (337) |
| Latino | 5 | (26) |
| White | 26 | (130) |
| Other | 3 | (13) |
| Education | ||
| Not high school graduate | 41 | (183) |
| High school graduate or GED | 36 | (161) |
| Some college/technical school or beyond | 23 | (106) |
| Self-reported HIV risk behavior | ||
| Men reporting sex with men | 29 | (159) |
| Injecting drug use | 16 | (80) |
| Had sex with men and injected drugs | 2 | (6) |
| Heterosexual contact | 45 | (267) |
| Heterosexual contact and injected drugs | 3 | (28) |
| Blood transfusion, blood components or tissue | 3 | (17) |
| Other | 2 | (11) |
| Mean CD4 count, cells/mm3 | 256 | |
| (SD) | 251 | |
| Median CD4 count, cells/mm3 | 193 | |
| Mean log10 HIV RNA level | 3.99 | |
| (SD) | 1.35 | |
| Median log10 HIV RNA level | 4.27 | |
Note: N = 524 represents participants receiving antiretroviral therapy who had 3-month and baseline interview with corresponding adherence, CD4, and HIV RNA data, missing values result in different total for each variable.